Search

Search Constraints

You searched for: Author/Creator Tebas, Pablo

Search Results

21. Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption. (1st October 2021)

22. Comparison of Cardiovascular Disease Risk Markers in HIV-Infected Patients Receiving Abacavir and Tenofovir: The Nucleoside Inflammation, Coagulation and Endothelial Function (Nice) Study. Issue 2 (February 2014)

23. Cytomegalovirus Immunoglobulin G (IgG) Titer and Coronary Artery Disease in People With Human Immunodeficiency Virus (HIV). (17th August 2022)

24. Debulking different Corona (SARS-CoV-2 delta, omicron, OC43) and Influenza (H1N1, H3N2) virus strains by plant viral trap proteins in chewing gums to decrease infection and transmission. (September 2022)

25. Deconstructing the Treatment Effect of Remdesivir in the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1: Implications for Critical Care Resource Utilization. (19th August 2021)

26. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial. Issue 2 (3rd March 2016)

27. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Issue 12 (December 2021)

28. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-blind, randomised, placebo-controlled, phase 3 trial. Issue 12 (December 2021)

29. Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. (1st November 2021)